Although this deal is structured to make SNUS the acquiring company, it is a reverse merger inasmuch as OncoGenex is contributing the bulk of the management team and pipeline and will own more than half the equity if milestones are met.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”